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LYR motif containing 1 (LYRM1) is a novel gene that is abundantly expressed in the adipose tissue of obese subjects and is
involved in insulin resistance. In this study, free fatty acids (FFAs) and tumor necrosis factor-α (TNF-α) are shown to upregulate
LYRM1 mRNA expression in 3T3-L1 adipocytes. Conversely, resistin and rosiglitazone exert an inhibitory eﬀect on LYRM1 mRNA
expression. These results suggest that the expression of LYRM1 mRNA is aﬀected by a variety of factors that are related to insulin
sensitivity. LYRM1 may be an important mediator in the development of obesity-related insulin resistance.
1.Introduction
Obesity has become a global public health problem in
recent decades [1]. Type 2 diabetes is characterized by an
inadequate beta-cell response to progressive insulin resist-
ance, which is typically accompanied by weight gain [2].
The increasing global prevalence of type 2 diabetes is tied to
rising rates of obesity [3]. Common obesity (complex poly-
genic obesity) results from interactions between genetic,
environmental, and psychosocial factors [4]. However, the
mechanisms underlying individual diﬀerences that lead to a
predisposition to obesity remain obscure.
In our earlier studies, we isolated and characterized
LYR motif containing 1 (LYRM1), a novel human gene
that was expressed at a high level in the omental adipose
tissue of obese patients. LYRM1 promotes preadipocyte
proliferation and inhibits apoptosis of preadipocytes [5, 6].
Overexpression of LYRM1 in 3T3-L1 adipocytes resulted in a
reduction of insulin-stimulated glucose uptake, an abnormal
mitochondrial morphology, decreasedintracellularATP syn-
thesis,anddecreasedmitochondrialmembranepotentials.In
addition, LYRM1 overexpression led to an excessive produc-
tion of intracellular reactive oxygen species [7]. Our ﬁndings
indicate that LYRM1 may be a new candidate gene related to
obesity-associated insulin resistance.
Several studies have shown that adipose tissue in obese
patients releases large amounts of free fatty acids (FFAs)
and several adipokines, including tumor necrosis factor-α
(TNF-α) and resistin [8–11]. All of these factors have been
identiﬁed as major regulators of insulin activity. A synthetic
activator of peroxisome proliferator-activated receptor-γ
(PPAR-γ) called rosiglitazone (BRL49653) is part of the
thiazolidinedione (TZD) class of drugs. Thiazolidinedione is
one of a few classes of drugs that acts primarily as an insulin
sensitizer by repressing, in mature adipocytes, the expression
and secretion of adipokines [12]. However, the underlying
molecular mechanisms of how these factors aﬀect insulin
sensitivity have not been clariﬁed.
In this study, we show that LYRM1 is a novel gene related
to obesity-associated insulin resistance. We hypothesize that
these factors (FFAs, TNF-α, and resistin) and drug (rosigli-
tazone) may have a potential regulatory mechanism in2 Experimental Diabetes Research
Table 1: Nucleotide sequences for primer and probe sets used in qPCR.
Gene Forward primer (5 –3 )P r o b e R e v e r s e p r i m e r ( 5  –3 )
LYRM1 CAGATGGATAGGGCGTGGATAAGG TGGTAATGCAGTCCAATCTCAATCCG GACAGCAGCAACCCGACAAGAAGT
β-actin CCTGAGGCTCTTTTCCAGCC TCCTTCTTGGGTATGGAATCCTGTGGC TAGAGGTCTTTACGGATGTCAACGT
obesity through the regulation of LYRM1 mRNA expression,
thereby aﬀecting insulin sensitivity. The purpose of this
study was to investigate the eﬀects of FFAs, TNF-α, resistin,
and rosiglitazone on LYRM1 mRNA expression in 3T3-L1
adipocytes.
2.MaterialsandMethods
2.1. 3T3-L1 Cell Culture and Treatment. 3T3-L1 cells were
cultured, maintained, and diﬀerentiated as previously de-
scribed [13]. Brieﬂy, after conﬂuence was achieved, the cells
were grown for 2 days in DMEM/high-glucose medium
(Gibco, Carlsbad, Calif, USA) supplemented with 10% fetal
bovine serum (FBS; Gibco, Carlsbad, Calif, USA), in a 5%
CO2 environment. Diﬀerentiation was subsequently induced
by incubation in a similar medium that was supplemented
with 0.5mmol/L 3-isobuty-1-methylxanthine (MIX; Sigma,
St. Louis, Mo, USA), 1μmol/L dexamethasone (Sigma, St.
Louis, Mo, USA), and 10μg/mL insulin (Sigma, St. Louis,
Mo,USA),for2days.Thecellswerethenplacedinamedium
containing 10μg/mL insulin for another 2 days. Afterwards,
the medium was replaced with DMEM containing only 10%
FBS, every 2 days.
On the eighth day after diﬀerentiation was induced, if
more than 90% of the cells showed the morphological and
biochemical properties of adipocytes, the cells were used
for experiments. After overnight incubation in serum-free
DMEM, the 3T3-L1 adipocytes were treated with either
10ng/mL TNF-α (T7539), 60ng/mL resistin (SRP4560),
0.5μM rosiglitazone (375004), which were all dissolved in
DMSO, or a 1mM FFA cocktail composed of palmitic
acid (p5585), oleic acid (O1008), and linoleic acid (L1376;
Sigma, St. Louis, Mo, USA). The high FFA solution was
prepared according to previously published methods [14,
15]. Brieﬂy, the fatty acids were dissolved in 2% (w/v)
fatty acid-free bovine serum albumin (BSA), with a stock
concentrationof100mM or an equivalentvolume of vehicle.
The stock solution was diluted 1:100 in DMEM to a ﬁnal
concentration of 1mM. After 12h or 24h of incubation in
the TNF-α, resistin rosiglitazone and high FFA solution, the
adipocytes were collected for subsequent experiments.
2.2. Quantitative Real-Time Reverse Transcriptase-Polymerase
C h a i nR e a c t i o n( R T - P C R ) .Total RNA was extracted from
3T3-L1 adipocytes using Trizol reagent (Invitrogen, Carls-
bad, Calif, USA). The extracted RNA was quantiﬁed by
spectrophotometry at 260nm. cDNA was synthesized from
1μg of total RNA using an AMV Reverse Transcriptase Kit
(Promega A3500; Promega, Madison, Wis, USA), accord-
ing to the manufacturer’s instructions. Real-time RT-PCR
was performed on an Applied Biosystems 7500 Sequence
Detection System (ABI 7500 SDS; Foster City, Calif, USA) by
following the manufacturer’s protocol.
Two primer sets were used for PCR analysis. A 259-
bp DNA fragment within the LYRM1 gene was used for
the quantiﬁcation of LYRM1 mRNA. The PCR product had
previously been cloned into the plasmid pMD-T 18 and
veriﬁed by DNA sequencing. Plasmid standards of known
copy numbers were used to generate a log-linear standard
curve, from which the copy numbers of LYRM1 could be
determined by real-time qPCR. A 110-bp region of the β-
actin gene was used to normalize the results. A standard
curve was generated from plasmids containing the β-actin
fragment. This standard curve was used to determine the
copy numbers of β-actin. Brieﬂy, the samples were incubated
at 95◦C for 10min for an initial denaturation, followed by 40
PCR cycles. Each cycle consisted of an incubation at 95◦Cf o r
15sandannealingat60◦Cfor1min.Theconcentrationratio
of LYRM1 to β-actin reﬂected the expression level of LYRM1
mRNA per cell. Primer and Taqman probe (Invitrogen,
Shanghai, China) sequences are shown in Table 1.
2.3. Statistical Analysis. Each experiment was performed at
least three times. All data was expressed as means ± SD.
Statistical analysis was performed using one-way ANOVA
using the SPSS 12.0 statistical software package (SPSS Inc.,
Chicago, Ill, USA). For all tests, P-values less than 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. The Expression of LYRM1 mRNA during the Conversion of
3T3-L1 Preadipocytes into Adipocytes. LYRM1 mRNAs were
expressed at very low levels In the 3T3-L1 preadipocytes.
During the conversion of 3T3-L1 cells to adipocytes, the
expression of the LYRM1 gene was gradually increased to
reach a stable level after the 10th day (Figure 1). More than
90% of the cells exhibited typical adipocyte morphology on
the 10th day.
3.2. The Eﬀect of FFAs on the Expression of LYRM1 mRNA in
3T3-L1 Adipocytes. To assess the eﬀect of FFAs on LYRM1
mRNA levels, we examined the expression of LYRM1 mRNA
in 3T3-L1 adipocytes treated with 1mM FFAs. Treatment
durations were for either 12 or 24h, 10 days after diﬀeren-
tiation was stimulated. We found that FFAs concentrations
of 1mM led to a time-dependent increase in LYRM1 mRNA
expression.LYRM1mRNAexpressiondramaticallyincreased
after 12h of exposure (Figure 2) and continued to increase
after a 24h exposure. At this time point, the expression of
LYRM1 mRNA was approximately 2-fold greater than the
control mRNA (P<0.001). This result shows that FFAsExperimental Diabetes Research 3
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Figure 1: The expression of the LYRM1 mRNA during the
conversion of 3T3-L1 cells to adipocytes. 3T3-L1 cells were induced
to diﬀerentiate, as described in “Materials and Methods” section.
Total RNA was harvested from the 3T3-L1 cells on alternate days
before (day −2, day 0) and after (day 2, day 4, day 6, day 8, day
10, and day 12) the switch from growth medium to diﬀerentiation
medium. LYRM1 mRNA levels were analyzed using quantitative
real-time RT-PCR and normalized to β-actin levels. The results are
presented as the means ± SE of six experiments.
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Figure 2: The eﬀe c to fF F A so nt h ee x p r e s s i o no fLYRM1 mRNA in
3T3-L1 adipocytes. Diﬀerentiated 3T3-L1 adipocytes were treated
with 1mM FFAs for the indicated periods (up to 24h). LYRM1
mRNA levels were analyzed using quantitative real-time RT-PCR
and normalized to β-actin levels. Results are presented as mean ±
SE of six experiments. ∗∗∗P<0.001 in comparison with basal levels
(untreated cells).
dramatically increased the mRNA expression level of the
LYRM1 gene.
3.3. The Eﬀects of TNF-α a n dR e s i s t i no nt h eE x p r e s s i o n
of LYRM1 mRNA in 3T3-L1 Adipocytes. We examined
LYRM1 mRNA expression 10 days after diﬀerentiation was
stimulated in 3T3-L1 adipocytes, which had been treated
with 10ng/mL TNF-α or 60ng/mL resistin. TNF-α slightly
increased LYRM1 mRNA expression in 3T3-L1 adipocytes
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Figure 3: The eﬀect of TNF-α on the expression of LYRM1
mRNA in 3T3-L1 adipocytes. Diﬀerentiated 3T3-L1 adipocytes
were treated with 10ng/mL TNF-α for the indicated periods (up
to24h).LYRM1mRNAlevelswereanalyzedusingquantitativereal-
timeRT-PCRandnormalizedtoβ-actinlevels.Resultsarepresented
as mean ± SE of six experiments. ∗P<0.05 in comparison with
basal levels (untreated cells).
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Figure 4: The eﬀect of resistin on the expression of LYRM1
mRNA in 3T3-L1 adipocytes. Diﬀerentiated 3T3-L1 adipocytes
were treated with 60ng/mL resistin for the indicated periods (up
to24h).LYRM1mRNAlevelswereanalyzedusingquantitativereal-
timeRT-PCRandnormalizedtoβ-actinlevels.Resultsarepresented
as mean ± SE of six experiments. ∗P<0.05 in comparison with
basal levels (untreated cells).
after 12h. mRNA expression continued to increase 24h after
treatment (P<0.05; Figure 3). Resistin showed a moderate
inhibitory eﬀect on LYRM1 gene expression at 12h; however,
expression was signiﬁcantly diminished 24h after resistin
treatment (P<0.05; Figure 4).
3.4. The Eﬀect of Rosiglitazone on the Expression of LYRM1
mRNA in 3T3-L1 Adipocytes. To study the relationship
between LYRM1 expression and a PPAR-γ agonist, we4 Experimental Diabetes Research
examined the eﬀect of rosiglitazone at 60ng/mL on 3T3-
L1 adipocytes. Twelve hours after treatment, LYRM1 mRNA
expressionin3T3-L1adipocytesdecreased.After24hmRNA
expression had signiﬁcantly diminished to approximately
half that of the control (P<0.001; Figure 5).
4. Discussion
The World Health Organization reports that at least one
billion adults are overweight and 300 million are obese. In
the absence of intervention, these numbers are expected to
rise [16]. Most obese individuals are insulin resistant, which
is an important etiological factor for type 2 diabetes mellitus.
Adipocytes are known to secrete a variety of mediators,
including FFA, TNF-α, and resistin, all of which regulate
insulin signaling and glucose uptake. LYRM1 is a recently
discovered gene that is involved in obesity-associated insulin
resistance [5, 7]. LYRM1 mRNA expression is upregulated
during conversion of 3T3-L1 cells to adipocytes, indicating
that the expression of the LYRM1 gene is involved in
adipocyte diﬀerentiation. From the 10th day after induction
of diﬀerentiation, the LYRM1 mRNA expression remained
at a stable high level, indicating that this clonal cell line
can be used to investigate the regulation of LYRM1 gene
expression. To elucidate the mechanisms by which LYRM1
is involved in the pathogenesis of obesity-associated insulin
resistance, we characterized how this gene is regulated by
factors that modulate insulin sensitivity. Furthermore, we
also investigated the eﬀects of rosiglitazone, which is a
PPAR-γ agonist, on LYRM1 mRNA expression in 3T3-L1
adipocytes.
Elevated concentrations of circulating free fatty acids
are characteristic of type 2 diabetes and are implicated in
the etiology of insulin resistance [17]. Insulin resistance is
thought to arise from impaired insulin signaling in target
tissues. Signaling is impaired due to augmentation of the
serine/threonine phosphorylation sites of insulin receptor
substrates (IRS-1 and IRS-2). In addition, insulin resistance
is compounded by a reduction of activated PI3-kinase
(PI3K) and an inhibition in the translocation of insulin-
stimulatedglucosetransporter4(GLUT4)[18,19].Anexcess
of FFAs causes the intracellular accumulation of metabolic
products such as ceramides, diacylglycerol, or acyl-CoA.
These FFA-derived products may lead to defects in insulin
signalingandglucosetransportthroughthePI3K-dependent
pathway [20, 21]. However, the underlying mechanisms of
these phenomena have not been clariﬁed. In this study, we
observed that FFAs added exogenously upregulated LYRM1
mRNA expression in 3T3-L1 adipocytes. We had previously
shown that LYRM1 overexpression can inhibit insulin-
stimulated glucose transport in adipocytes [7]. We observed
that an excess of FFAs might induce insulin resistance.
Resistance could partly be induced through the upregulation
of LYRM1 expression, which would inhibit glucose uptake in
adipocytes. These ﬁndings support and extend other results
in the literature that investigate the eﬀects of FFAs on insulin
signaling.
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Figure 5: The eﬀect of rosiglitazone on the expression of LYRM1
mRNA in 3T3-L1 adipocytes. Diﬀerentiated 3T3-L1 adipocytes
were treated with 0.5μM rosiglitazone for the indicated periods (up
to24h).LYRM1mRNAlevelswereanalyzedusingquantitativereal-
timeRT-PCRandnormalizedtoβ-actinlevels.Resultsarepresented
as mean ± SE of six experiments. ∗∗P<0.01, ∗∗∗P<0.001 in
comparison with basal levels (untreated cells).
As one of the most widely studied cytokines, TNF-α is
reported to modulate insulin resistance [10]. A key role for
TNF-α in obesity-related insulin resistance was identiﬁed
when TNF-α or TNF-α receptors were deleted in both diet-
induced obese mice and leptin-deﬁcient ob/ob mice, which
resulted in signiﬁcantly improved insulin sensitivity [22].
However, the infusion of TNF-α-neutralizing antibodies into
obese, insulin-resistant subjects, or type 2 diabetic patients,
did not improve insulin sensitivity [23, 24]. In this study,
we observed that TNF-α slightly upregulates LYRM1 mRNA
expression in 3T3-L1 adipocytes. There is a need for further
studies in human adipocytes. Currently, we suggest that
TNF-α-induced insulin resistance is only indirectly involved
in increased LYRM1 expression.
Resistin was identiﬁed as a gene that was downregulated
by TZD in mouse adipocytes [11]. In rodents, the circulating
levels of resistin increased in obesity [25]. Furthermore, an
increase in serum resistin levels induced insulin resistance in
several rat and mouse models, including after acute admin-
istration [26]. Recombinant resistin caused severe hepatic
insulin resistance in rodents [26]. However, a study observed
a decrease in fasting glucose, improved glucose tolerance and
enhanced insulin sensitivity in resistin knockout mice [27].
In humans, there is considerable controversy surrounding
the role of resistin. We showed that resistin exerts a moderate
inhibitory eﬀect on LYRM1 gene expression in 3T3-L1
adipocytes. This data suggests that LYRM1 and resistin inter-
act during the development of obesity-associated insulin
resistance.
In this study, we observed that rosiglitazone inhibits
LYRM1 gene expression in 3T3-L1 adipocytes. Rosiglitazone
is part of the TZD class of drugs, which act as insulin
sensitizers and agonists for the transcription factor PPAR-γ.
PPAR-γ is a member of three nuclear receptor isoforms (the
other two are PPAR-α and PPAR-δ), which are encodedExperimental Diabetes Research 5
by diﬀerent genes. PPAR-γ is the master regulator of adi-
pogenesis, being both essential and suﬃcient for adipocyte
diﬀerentiation[28].Italsoupregulatestheexpressionoffatty
acid transporter proteins (FATP-1 and D036) [29]. Rosigli-
tazone suppresses TNF-α mediated inhibition of adipocyte
diﬀerentiation, whilst TNF-α decreased the expression of
PPAR-γ [30]. TZDs inhibit resistin gene expression in
human macrophages [31, 32] and lower serum resistin levels
in humans as well as rodents [33–35]. We deduced that
rosiglitazone inhibits LYRM1 gene expression most likely
through PPAR-γ.
Our results demonstrate that LYRM1 mRNA expression
is greatlyaﬀectedbyrosiglitazone, FFAs,andtwoadipokines,
TNF-α and resistin. These two adipokines are involved in
the regulation of insulin sensitivity. The upregulation or
downregulation of LYRM1expression may be strongly linked
to FFA or rosiglitazone-related insulin resistance. Recently,
LYRM1 in rat myoblasts has been shown to negatively regu-
late the function of IRS-1 and PI3K/Akt, whilst decreasing
GLUT4 translocation and glucose uptake in response to
insulin (L6) [36]. However, a more precise characterization
of the physiological activities of LYRM1 is required to fully
understand these processes.
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